Francesca writes about a broad range of policy and regulatory topics, including intellectual property rights. However, her main areas of expertise are pricing and reimbursement and how medicines may or may not make it to patients. She writes about developments in Europe and is also expanding coverage in emerging markets, including Latin America and the Middle East. Francesca writes for Pink Sheet, Scrip and In Vivo.
Latest from Francesca Bruce
Weight loss drugs have likely proven to be the most challenging medicines to introduce to the National Health Service in England, and lessons should be learned in preparation for other game changing products.
Smaller biotech companies without the regulatory resources of big pharma should approach the UK medicines regulator and health technology appraisal body for early, informal discussions on how to generate the right evidence.
A new survey of French healthcare professionals reveals concerns that France is increasingly being excluded from major international clinical studies.
Leem, the French industry association, is reaching out to patients, carers and the general public with the aim of building better policies to improve access to medicines and ensure the pharmaceutical industry is competitive.
Norway’s pharmaceutical industry association says it is waiting to hear from the ministry of health about how it will address the country’s low willingness to pay for innovation.
European pricing and reimbursement processes, including in the UK, are on hold for now.